Search - tctmd.com

Displaying 61 - 80 of 164

Sort: Relevancy | Date

News Daily News

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Michael O'Riordan

June 20, 2018

News Conference News CRT 2018

Transcatheter Fix for Native Aortic Valve Regurgitation ‘Not Optimal’ but Getting Better

Shelley Wood

March 05, 2018

News Daily News

Preexisting Prosthesis-Patient Mismatch Signals Worse Aortic Valve-in-Valve Outcomes

Todd Neale

January 17, 2018

News Daily News

REPRISE III in Print: Now With Comparison Between Lotus, Evolut R

Shelley Wood

January 05, 2018

News Daily News

New-Generation TAVR Devices Outperform Predecessors in Treating Pure Native AR: Registry

Caitlin E. Cox

November 30, 2017

News Conference News TCT 2017

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

Michael O'Riordan

October 31, 2017

News Daily News

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Michael O'Riordan

September 27, 2017

News Conference News PCR London Valves 2017

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

Shelley Wood

September 27, 2017

News Industry News

Medtronic Announces CE Mark and European Launch of CoreValve(TM) Evolut(TM) PRO Transcatheter Valve with Advanced Sealing

August 01, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2017

Shelley Wood

July 31, 2017

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Daily News

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Michael O'Riordan

June 26, 2017

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Shelley Wood

June 19, 2017

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

News Conference News TVT 2017

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Shelley Wood

June 12, 2017

News Daily News

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Michael O'Riordan

June 06, 2017

News Conference News EuroPCR 2017

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

Shelley Wood

June 02, 2017

News Conference News EuroPCR 2017

More Early Stroke With SAVR Than TAVR in SURTAVI

Shelley Wood

May 18, 2017

News Conference News EuroPCR 2017

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Caitlin E. Cox

May 17, 2017

Advertisement

Leaflet Thrombosis After TAVR Not Linked With Stroke, TIA, or Mortality Risk

Transcatheter Fix for Native Aortic Valve Regurgitation ‘Not Optimal’ but Getting Better

Preexisting Prosthesis-Patient Mismatch Signals Worse Aortic Valve-in-Valve Outcomes

REPRISE III in Print: Now With Comparison Between Lotus, Evolut R

New-Generation TAVR Devices Outperform Predecessors in Treating Pure Native AR: Registry

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

Medtronic Announces CE Mark and European Launch of CoreValve(TM) Evolut(TM) PRO Transcatheter Valve with Advanced Sealing

TCTMD’s Top 10 Most Popular Stories for July 2017

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

My Takeaways From EuroPCR 2017: Everything Perfect, Until It’s Not

More Early Stroke With SAVR Than TAVR in SURTAVI

TAVR Durability: Some Reassurances From CoreValve Trials Out to 9 Years

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content